Pharmacopeia Inc. is continuing its long-running show with Schering-Plough Corp., which signed on for another three years in an agreement with a potential value "beyond an eight-figure deal," said Pharmacopeia's chief financial officer. (BioWorld Today)

Pharmacopeia Inc. is continuing its long-running show with Schering-Plough Corp., which signed on for another three years in an agreement with a potential value "beyond an eight-figure deal," said Pharmacopeia's chief financial officer. (BioWorld Today)

Flamel Technologies SA again has partnered its recombinant human insulin product, Basulin; this time, signing a deal with Bristol-Myers Squibb Co. valued at up to $165 million. (BioWorld Today)